Athena Neurosciences, Inc.
Records under this name other than patents Athena Neurosciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Athena Neurosciences, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,982,084 | Prevention and Treatment of Amyloidogenic Disease Formerly held Term ended Ended no later than Sep 23, 2019 · Low confidence | Term ended | Ended no later than Sep 23, 2019 | Low confidence |
| US 7,166,580 | Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4 Formerly held Term ended Term ended Sep 15, 2019 · Medium confidence | Term ended | Term ended Sep 15, 2019 | Medium confidence |
| US 6,787,140 | Prevention and treatment of amyloidogenic disease Formerly held Term ended Ended no later than Jun 26, 2019 · USPTO record | Term ended | Ended no later than Jun 26, 2019 | USPTO record |
| US 7,014,855 | Prevention and Treatment of Amyloidogenic Disease Formerly held Term ended Term ended May 30, 2019 · Medium confidence | Term ended | Term ended May 30, 2019 | Medium confidence |
| US 6,866,850 | Prevention and Treatment of Amyloidogenic Disease Formerly held Term ended Term ended Mar 17, 2019 · Medium confidence | Term ended | Term ended Mar 17, 2019 | Medium confidence |
| US 6,787,138 | Prevention and treatment of amyloidogenic disease Formerly held Term ended Term ended Jan 16, 2019 · USPTO record | Term ended | Term ended Jan 16, 2019 | USPTO record |
| US 6,787,139 | Prevention and treatment of amyloidogenic disease Formerly held Term ended Ended no later than Nov 30, 2018 · USPTO record | Term ended | Ended no later than Nov 30, 2018 | USPTO record |
| US 6,787,143 | Prevention and treatment of amyloidogenic disease Formerly held Term ended Ended no later than Nov 30, 2018 · USPTO record | Term ended | Ended no later than Nov 30, 2018 | USPTO record |
| US 6,787,144 | Prevention and treatment of amyloidogenic disease Formerly held Term ended Ended no later than Nov 30, 2018 · USPTO record | Term ended | Ended no later than Nov 30, 2018 | USPTO record |
| US 6,787,523 | Prevention and treatment of amyloidogenic disease Formerly held Term ended Ended no later than Nov 30, 2018 · USPTO record | Term ended | Ended no later than Nov 30, 2018 | USPTO record |